Runnymede Capital Advisors, Inc. Viking Therapeutics, Inc. Transaction History
Runnymede Capital Advisors, Inc.
- $114 Billion
- Q4 2024
A detailed history of Runnymede Capital Advisors, Inc. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Runnymede Capital Advisors, Inc. holds 6,290 shares of VKTX stock, worth $189,769. This represents 0.22% of its overall portfolio holdings.
Number of Shares
6,290Holding current value
$189,769% of portfolio
0.22%Shares
1 transactions
Others Institutions Holding VKTX
# of Institutions
462Shares Held
65MCall Options Held
5.76MPut Options Held
3.4M-
Vanguard Group Inc Valley Forge, PA10.2MShares$307 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$182 Million0.01% of portfolio
-
State Street Corp Boston, MA4.67MShares$141 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.12MShares$63.9 Million0.01% of portfolio
-
Morgan Stanley New York, NY1.87MShares$56.6 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.31B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...